Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study
Authors:
- 25 August 2014
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 29 (3) , 668-676
Abstract
Treatment for follicular lymphoma (FL) improved with rituximab. In Sweden, first-line rituximab was gradually introduced between 2003 and 2007, with regional differences. The first national guidelines for FL were published in November 2007, recommending rituximab in first-line therapy. Using the population-based Swedish Lymphoma Registry, 2641 patients diagnosed with FL from 2000 to 2010 were identified and characterized by year and region of diagnosis, age (median, 65 years), gender (50% men), first-line therapy and clinical risk factors. Overall and relative survivals were estimated by calendar periods (2000–2002, 2003–2007 and 2008–2010) and region of diagnosis. With each period, first-line rituximab use and survival increased. Survival was superior in regions where rituximab was quickly adopted and inferior where slowly adopted. These differences were independent in multivariable analyses. Ten-year relative survival for patients diagnosed 2003–2010 was 92%, 83%, 78% and 64% in the age groups 18–49, 50–59, 60–69 and 70, respectively. With increasing rituximab use, male sex emerged as an adverse factor. Survival improved in all patient categories, particularly in elderly women. The introduction and the establishment of rituximab have led to a nationwide improvement in FL survival. However, rituximab might be inadequately dosed in younger women and men of all ages.Keywords
This publication has 41 references indexed in Scilit:
- The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCLBlood, 2012
- Direct Effect of Rituximab in B-Cell–Derived Lymphoid Neoplasias: Mechanism, Regulation, and PerspectivesMolecular Cancer Research, 2011
- Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*European Journal of Haematology, 2010
- Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 studyBlood, 2008
- An approach to estimation in relative survival regressionBiostatistics, 2008
- Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology StudyJournal of Clinical Oncology, 2007
- Prognostic Factors in Diffuse Large Bcell Lymphoma Treated by Riskadopted TherapyInternal Medicine, 2006
- Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood, 2005
- New Treatment Options Have Changed the Survival of Patients With Follicular LymphomaJournal of Clinical Oncology, 2005
- STAGE I AND II NON-HODGKIN’S LYMPHOMAAmerican Journal of Roentgenology, 1973